Literature DB >> 1433606

Interleukin-6 in renal cell carcinoma.

T Tsukamoto1, Y Kumamoto, N Miyao, N Masumori, A Takahashi, M Yanase.   

Abstract

We studied interleukin-6 production in 4 human renal cell carcinoma cell lines and measured the serum level in 71 patients with renal cell carcinoma, thus, clarifying a relationship between interleukin-6 secretion and an occurrence of the paraneoplastic syndrome in the carcinoma. Interleukin-6 was produced by 3 cell lines and detected in 25% of the patients. The level of interleukin-6 did not directly correlate with tumor volume and the differentiation grade of the carcinoma. However, the positive rate increased with progression of the stage. The serum level affected the 5-year survival of patients without distant metastasis. When serum interleukin-6 was elevated patients had a significantly higher frequency of unexplained fever and an elevation of acute phase proteins. These results suggest that some renal cell carcinomas can produce interleukin-6 and this cytokine is responsible for several paraneoplastic syndromes in the carcinoma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1433606     DOI: 10.1016/s0022-5347(17)37026-x

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  19 in total

1.  Serum interleukin-6 and -10 levels in patients with gastric cancer.

Authors:  Masahide Ikeguchi; Tomoko Hatada; Manabu Yamamoto; Takanori Miyake; Tomonori Matsunaga; Youji Fukumoto; Yoshinori Yamada; Kenji Fukuda; Hiroaki Saito; Shigeru Tatebe
Journal:  Gastric Cancer       Date:  2009-06-27       Impact factor: 7.370

2.  Expression of the interleukin 6 receptor in primary renal cell carcinoma.

Authors:  V Costes; J Liautard; M C Picot; M Robert; N Lequeux; J Brochier; P Baldet; J F Rossi
Journal:  J Clin Pathol       Date:  1997-10       Impact factor: 3.411

3.  Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma.

Authors:  Maurizio Soresi; Lydia Giannitrapani; Fabio D'Antona; Ada-Maria Florena; Emanuele La Spada; Angela Terranova; Melchiorre Cervello; Natale D'Alessandro; Giuseppe Montalto
Journal:  World J Gastroenterol       Date:  2006-04-28       Impact factor: 5.742

4.  Effect of IL-6 on tumor cell invasion of vascular endothelial monolayers.

Authors:  Y Kitamura; I Morita; Z Nihei; Y Mishima; S Murota
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

5.  Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma.

Authors:  G Y Chau; C W Wu; W Y Lui; T J Chang; H L Kao; L H Wu; K L King; C C Loong; C Y Hsia; C W Chi
Journal:  Ann Surg       Date:  2000-04       Impact factor: 12.969

6.  Interleukin-6 (IL-6) and C-reactive protein (CRP) concentration prior to total nephrectomy are prognostic factors in localized renal cell carcinoma (RCC).

Authors:  Michał Hrab; Karolina Olek-Hrab; Andrzej Antczak; Zbigniew Kwias; Tomasz Milecki
Journal:  Rep Pract Oncol Radiother       Date:  2013-07-26

Review 7.  [Paraneoplastic syndrome in renal cell carcinoma].

Authors:  J Bedke; S Buse; M Kurosch; A Haferkamp; D Jäger; M Hohenfellner
Journal:  Urologe A       Date:  2007-01       Impact factor: 0.639

8.  Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma.

Authors:  Ganesh S Palapattu; Blaine Kristo; Jacob Rajfer
Journal:  Rev Urol       Date:  2002

9.  Prognostic role of interleukin-6 in renal cell carcinoma: a meta-analysis.

Authors:  Y Wang; Y Zhang
Journal:  Clin Transl Oncol       Date:  2019-08-13       Impact factor: 3.405

10.  Expression of VEGF, EGFR, and IL-6 in gastric adenomas and adenocarcinomas by endoscopic submucosal dissection.

Authors:  Shin-Ae Lee; Seok-Reyol Choi; Jin-Seok Jang; Jong-Hun Lee; Myung-Hwan Roh; Sang Ock Kim; Min-Chan Kim; Su-Jin Kim; Jin-Sook Jeong
Journal:  Dig Dis Sci       Date:  2009-09-12       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.